Efficacy of a bivalent inactivated non-adjuvanted feline calicivirus vaccine: relation between in vitro cross-neutralization and heterologous protection in vivo.
Feline calicivirus (FCV) is a major pathogen of the cat characterized by a strong genomic, antigenic and clinical diversity. Despite vaccination, FCV infection is highly prevalent, and for a few years, outbreaks of virulent systemic disease (VSD) have been reported in North America and Europe. An inactivated non-adjuvanted bivalent vaccine was recently developed by combining antigens derived from two broadly cross-reactive FCV strains. The antigenic relatedness between the vaccine strains and other antigenic variants was demonstrated by cross-neutralization studies in vitro. This study showed that vaccine-induced protection against heterologous challenges was correlated to in vitro cross-neutralization, and it validated the use of cross-neutralization tests to select vaccine FCV strains. This correlation applies also for the highly virulent strains causing VSD (VS-FCV).
Merial S.A.S., Lyon Laboratories, Research and Development Department, 254 rue Marcel Mérieux, 69007 Lyon, France. herve.poulet@merial.com
H
H
Poulet
D
D
Jas
C
C
Lemeter
C
C
Coupier
S
S
Brunet
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D017250:Caliciviridae Infections / Q000517:prevention & control*; D017927:Calicivirus, Feline / Q000276:immunology*; D002415:Cats; D003429:Cross Reactions; D005060:Europe; D009500:Neutralization Tests; D009656:North America; D010802:Phylogeny; D012367:RNA, Viral / Q000235:genetics; D017422:Sequence Analysis, DNA; D017385:Sequence Homology; D012720:Severity of Illness Index; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D012367:RNA, Viral; D014765:Viral Vaccines